Menu
GWAS Study

Genetic variation in the HLA region is associated with susceptibility to herpes zoster.

Crosslin DR, Carrell DS, Burt A et al.

25297839 PubMed ID
GWAS Study Type
22529 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

CD
Crosslin DR
CD
Carrell DS
BA
Burt A
KD
Kim DS
UJ
Underwood JG
HD
Hanna DS
CB
Comstock BA
BE
Baldwin E
DA
de Andrade M
KI
Kullo IJ
TG
Tromp G
KH
Kuivaniemi H
BK
Borthwick KM
MC
McCarty CA
PP
Peissig PL
DK
Doheny KF
PE
Pugh E
KA
Kho A
PJ
Pacheco J
HM
Hayes MG
RM
Ritchie MD
VS
Verma SS
AG
Armstrong G
SS
Stallings S
DJ
Denny JC
CR
Carroll RJ
CD
Crawford DC
CP
Crane PK
MS
Mukherjee S
BE
Bottinger E
LR
Li R
KB
Keating B
MD
Mirel DB
CC
Carlson CS
HJ
Harley JB
LE
Larson EB
JG
Jarvik GP
Chapter II

Abstract

Summary of the research findings

Herpes zoster, commonly referred to as shingles, is caused by the varicella zoster virus (VZV). VZV initially manifests as chicken pox, most commonly in childhood, can remain asymptomatically latent in nerve tissues for many years and often re-emerges as shingles. Although reactivation may be related to immune suppression, aging and female sex, most inter-individual variability in re-emergence risk has not been explained to date. We performed a genome-wide association analyses in 22,981 participants (2280 shingles cases) from the electronic Medical Records and Genomics Network. Using Cox survival and logistic regression, we identified a genomic region in the combined and European ancestry groups that has an age of onset effect reaching genome-wide significance (P>1.0 × 10(-8)). This region tags the non-coding gene HCP5 (HLA Complex P5) in the major histocompatibility complex. This gene is an endogenous retrovirus and likely influences viral activity through regulatory functions. Variants in this genetic region are known to be associated with delay in development of AIDS in people infected by HIV. Our study provides further suggestion that this region may have a critical role in viral suppression and could potentially harbor a clinically actionable variant for the shingles vaccine.

2,016 European ancestry cases, 16,407 European ancestry controls, 173 African ancestry cases, 3,312 African ancestry controls, 41 Hispanic cases, 580 Hispanic controls

Chapter III

Study Statistics

Key metrics and study information

22529
Total Participants
GWAS
Study Type
No
Replicated
African unspecified, Hispanic or Latin American, European
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.